Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN4RV0)

Drug Name

PRX-00023 Drug Info

Synonyms

Naluzotan; 740873-06-7; PRX-00023; UNII-LQ54E5B4EW; LQ54E5B4EW; CHEMBL209821; Naluzotan [USAN:INN]; PRX 00023; Naluzotan (USAN/INN); SCHEMBL678016; ZINC3963096; BCP20177; BDBM50187377; CS-6740; SB16847; N-[3-[4-[4-(cyclohexylmethylsulfonylamino)butyl]piperazin-1-yl]phenyl]acetamide; HY-14848; AN-27536; D09358; L001689; 833C676; Acetamide, N-(3-(4-(4-(((cyclohexylmethyl)sulfonyl)amino)butyl)-1-piperazinyl)phenyl)-; N-(3-[4-(4-Cyclohexylmethanesulfonylaminobutyl)piperazin-1-yl]phenyl)acetamide

Indication

Disease Entry	ICD 11	Status	REF
Mood disorder	6A60-6E23	Discontinued in Phase 2	[1]

Cross-matching ID

PubChem CID: 11430856
CAS Number: CAS 740873-06-7
TTD Drug ID: DMN4RV0
VARIDT Drug ID: DR00749

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[3]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[4]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[5]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[6]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[7]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[1]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[8]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[9]
Treximet	DMU54QB	Migraine	8A80	Approved	[10]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
2	PRX-00023, a selective serotonin 1A receptor agonist, reduces ultrasonic vocalizations in infant rats bred for high infantile anxiety.Pharmacol Biochem Behav.2009 Nov;94(1):8-15.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
5	Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
6	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
7	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
8	Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
9	Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
10	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
11	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)